MSD Germany has appointed Dr Susanne Fiedler as CEO to take over from Hanspeter Quodt, who steps after seven years in the post.
Dr Fielder first joined the German operations of Merck & Co in 1997, when she took up a role in market research.
She then moved to market, initially as a product manager and later as a marketing manager and then a business unit head with responsibility for a number of MSD products.
Since then Dr Fielder has served in the US, where MSD operates at Merck & Co, as global brand leader for the diabetes treatments Januvia and Janumet, before taking up a Sydney-based role as managing director of MSD Australia and New Zealand.
She will officially take on her new role on 1 February, when Quodt moves to a new European level position.
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.